Phase II study of patients with hormone-naive prostate cancer with a rising prostate specific antigen: granulocyte-macrophage colony-stimulating factor (GM-CSF) [sargramostim], thalidomide plus docetaxel

Trial Profile

Phase II study of patients with hormone-naive prostate cancer with a rising prostate specific antigen: granulocyte-macrophage colony-stimulating factor (GM-CSF) [sargramostim], thalidomide plus docetaxel

Discontinued
Phase of Trial: Phase II

Latest Information Update: 22 Mar 2016

At a glance

  • Drugs Sargramostim (Primary) ; Docetaxel; Thalidomide
  • Indications Prostate cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 24 Aug 2008 Actual patient number (9) added as reported by ClinicalTrials.gov.
    • 24 Aug 2008 Trial sponsor changed from Berlex to Bayer as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top